Key Points BioNTech recently experienced a clinical trial failure, followed by a clinical success several weeks later. The company's deep pipeline could enable it to launch brand-new, lucrative products over the next few years. 10 stocks we like better than BioNTech Se › It has been a volatile year for BioNTech (NASDAQ: BNTX) , an mRNA-based vaccine specialist. The company's financial results have been unimpressive as its coronavirus business continues to struggle, but a major clinical trial win from Moderna (NASDAQ: MRNA) , which also develops mRNA-based vaccines, helped jolt BioNTech's stock. The company's own clinical progress has been mixed, though.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.